Eli Lilly (LLY)

Global financial markets are currently navigating a treacherous landscape marked by a pronounced surge in investor risk aversion. As of October 16, 2025, a potent cocktail of persistent geopolitical instability, enduring economic uncertainties, and lingering concerns over banking sector fragility has compelled investors to retreat from riskier assets, fundamentally reshaping

Shares of Eli Lilly and Novo Nordisk move lower in Thursday's after-hours session after President Trump indicated weight-loss drugs are going to go down in price.

These companies are investing heavily into their pipelines and the payoff for long-term investors can be substantial.

The smaller drugmaker is looking to disrupt a fast-growing market.

Investors should be able to count on these stocks to deliver steady and growing income over the long term.

Novo Nordisk’s $4.7B Akero deal boosts its metabolic health pipeline, targeting Eli Lilly’s lead in obesity and liver disease treatments

Orforglipron meets key endpoints in Phase 3 trials, showing A1C reduction, weight loss, and cardiovascular benefits for type 2 diabetes.

Eli Lilly's stock shows robust momentum and strong analyst support, driven by solid fundamentals and positive market sentiment, while upcoming earnings releases remain a focal point for investors.

The company is one of two major players in the rapidly growing obesity drug market. Yet, the stock has lost half its value.

Regardless of your investing knowledge or experience, you can't go wrong with these three behemoths in your portfolio.

Despite the company's run in recent years, it's not too late to buy.

Insiders are buying these three healthcare companies that have catalysts to drive their share prices higher in the upcoming years.

The blood-based test is aimed at aiding the initial assessment for Alzheimer’s disease and other causes of cognitive decline in the primary-care setting in patients aged 55 and older.

Wall Street, according to CNBC's Mad Money host Jim Cramer, is no longer a monolithic entity but rather a fractured landscape operating under three distinct economic realities. In recent broadcasts around October 8 and 9, 2025, Cramer articulated a vision of the market segmented into a booming Artificial Intelligence and

The company is readying to take on pharma giants Novo Nordisk and Eli Lilly.

Is it too late to get on the bandwagon?

This beaten-down drugmaker is well positioned to turn things around.

Now may be the time to invest in drug companies, as they just slipped the tariff noose.

The fallen pharma giant could make a big comeback in 2026.